Article Text

Download PDFPDF
ESRA19-0159 A prospective global registry of real-world outcomes using spinal cord stimulation systems for chronic pain
  1. S Love-Jones1,
  2. S Thomson2,
  3. R Rauck3,
  4. RELIEFStudy Group4,
  5. R Woon4 and
  6. R Jain4
  1. 1Southmead Hospital, Bristol, UK
  2. 2Basildon and Thurrock University Hospitals NHS, Pain Management, Basildon, UK
  3. 3Carolinas Pain Institute, Pain Management, Winston-Salem, USA
  4. 4Boston Scientific, Clinical, Valencia, USA


Background and aims Real world evidence (RWE) derived from clinical registries via application of advanced data analytics represents a potentially important aspect of the on-going rational assessment and future development of commercially-available spinal cord stimulation (SCS) devices. We present here a prospective global registry designed to evaluate long-term, clinical application of neurostimulation therapy for pain.

Methods This is a prospective, multicenter global registry (RELIEF Registry, Boston Scientific) that assesses up to 1700 participants at up to 80 centers ( Identifier: NCT01719055). These assessments will encompass pain relief, satisfaction, quality of life, safety, and other aspects associated with the real-world clinical use of SCS. Eligible study participants are trialed for ‘on label’ use only with a commercially-approved SCS system (Boston Scientific). All permanently-implanted subjects are followed out to 36-months.

Results A total of 1,151 subjects have been assessed out to 3-years post-implantation. Patient satisfaction (PGIC) assessment determined that 88% of registry participants reported overall therapeutic improvement within the span of this 3-year duration. In addition, a low incidence of explants due to device-related complications of 7.9% was determined with only 2.4% indicating that this was due to inadequate pain relief (% explant per year: 3.6%).

Conclusions Real-world evidence derived from large patient registries is needed to assess patient quality of life and device longevity when using SCS to treat chronic pain. the 3-year results of this prospective, real-world registry demonstrate a low percent explant rate per year and a high percentage of patients reporting therapeutic improvement when using an SCS device to treat their chronic pain.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.